Arcellx, Inc. (ACLX) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $115.11: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10. Specifically: Below-average business quality; Rich valuation.
Arcellx is a clinical-stage biotech developing D-Domain-based CAR-T therapies, with lead program anito-cel (BCMA-targeting ddCAR) for relapsed/refractory multiple myeloma co-developed with Kite Pharma (Gilead). A BLA was submitted to the FDA in December 2025 with PDUFA date... Read more
Sell if holding. Engine safety override at $115.11: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10. Specifically: Below-average business quality; Rich valuation. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.1/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
About Arcellx, Inc.
About Arcellx, Inc.
Arcellx's lead program anito-cel (anitocabtagene autoleucel) achieved a 96% overall response rate across 117 patients in the pivotal Phase 2 iMMagine-1 trial of relapsed or refractory multiple myeloma (rrMM) as of the October 2025 data cutoff, with a BLA submitted to the FDA in December 2025 and a PDUFA action date of December 23, 2026. The global MM market was estimated at approximately $26 billion in 2025, with the total addressable CAR-T market for rrMM valued at $12 billion or more. MM affects approximately 36,000 new U.S. patients per year and is currently considered incurable.
Arcellx generates no product revenue and had an accumulated deficit of $725.8 million as of December 31, 2025, with net losses of $228.9 million in 2025 versus $107.3 million in 2024. Revenue comes primarily through its collaboration with Kite Pharma (a Gilead company), covering co-development and co-commercialization of anito-cel and other autologous and non-autologous CAR-T candidates using the D-Domain BCMA binder. Kite is manufacturing anito-cel for the Phase 3 iMMagine-3 trial, expected to complete enrollment by mid-2026 in second through fourth line rrMM patients. Beyond anito-cel, the company is advancing ARC-SparX programs ACLX-001 (BCMA-targeting, for which Kite holds a license option), ACLX-002 (CD123 in AML/MDS), and ACLX-004 (CD33/CD123 in AML). Phase 1 dosing of anito-cel in generalized Myasthenia Gravis began in the second half of 2025, the first autoimmune application outside oncology.
Show full overview
The entire commercial thesis rested on anito-cel's FDA decision expected December 23, 2026, with the 10-K explicitly acknowledging the company has "only one product candidate in late-stage clinical development," making any clinical hold, manufacturing failure, or regulatory rejection a binary event for the enterprise. This pipeline binary risk was resolved for public shareholders when Gilead Sciences completed its acquisition of Arcellx in April 2026 via Form 8-K — at $115.00 per share plus one CVR representing the right to receive $5.00 if cumulative worldwide anito-cel sales exceed $6.0 billion by December 31, 2029.
See also: Healthcare · Biotechnology
From Arcellx, Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-06-15Recent Developments — Arcellx, Inc.
Latest news
- NEWS Cantor Fitzgerald Suspends Neutral Rating on Arcellx — benzinga Apr 29, 2026 negative
- NEWS Gilead Acquisition Spree Continues With $3 Billion Tubulis Deal — benzinga Apr 7, 2026 neutral
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineanito-cel10-K Item 1A: 'have only one product candidate in late-stage clinical development...anito-cel, there is no assurance that the safety measures'
- MEDIUMSupplierKite10-K Item 1A: 'We depend on Kite for certain development, manufacturing and commercialization activities with respect to certain of our product candidates'
Material Events(8-K, last 90d)
- 2026-04-28Item 2.01HIGHArcellx acquisition by Gilead Sciences completed April 28, 2026 via tender offer and merger. Shareholders received $115.00/share plus one CVR ($5.00 contingent on anito-cel cumulative worldwide sales exceeding $6.0 billion by December 31, 2029).SEC filing →
- 2026-04-28Item 5.01HIGHChange of control: Gilead Sciences completed acquisition of Arcellx effective April 28, 2026. Ravens Sub, Inc. (Gilead subsidiary) merged with and into Arcellx, with Arcellx surviving as a wholly owned Gilead subsidiary.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $115.11: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10. Specifically: Below-average business quality; Rich valuation. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $114.87. Score 4.1/10, moderate confidence.
Take-profit target: $112.83 (-1.9% upside). Prior stop was $114.87. Stop-loss: $114.87.
Concentration risk — Pipeline: anito-cel; Target reached (-15.2% upside); Quality below floor (2.0 < 4.0).
Arcellx, Inc. trades at a P/E of N/A (forward -77.7). TrendMatrix value score: 3.0/10. Verdict: Sell.
14 analysts cover ACLX with a consensus score of 2.6/5. Average price target: $112.
What does Arcellx, Inc. do?Arcellx is a clinical-stage biotech developing D-Domain-based CAR-T therapies, with lead program anito-cel...
Arcellx is a clinical-stage biotech developing D-Domain-based CAR-T therapies, with lead program anito-cel (BCMA-targeting ddCAR) for relapsed/refractory multiple myeloma co-developed with Kite Pharma (Gilead). A BLA was submitted to the FDA in December 2025 with PDUFA date December 23, 2026; Gilead agreed to acquire Arcellx for $115/share plus a CVR in February 2026, with the merger completing April 2026.